

- Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013;31:2500–2510.
- Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. *N Engl J Med* 2009;360:902–911.
- Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. *Cancer Epidemiol Biomarkers Prev* 2009;18:1033–1040.
- Cancer Facts & Figures 2013*. Atlanta: American Cancer Society; 2013.
- Choy JT, Brannigan RE. The determination of reproductive safety in men during and after cancer treatment. *Fertil Steril* 2013;100:1187–1191.
- Stensheim H, Klungsoyr K, Skjaerven R, et al. Birth outcomes among offspring of adult cancer survivors: a population-based study. *Int J Cancer* 2013;133:2696–2705.
- Signorello LB, Mulvihill JJ, Green DM, et al. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. *J Clin Oncol* 2012;30:239–245.
- Howlander N, Noone A, Krapcho M, et al. *SEER Cancer Statistics Review, 1975-2010*. Bethesda, MD: National Cancer Institute; 2013.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Bart J, Groen HJ, van der Graaf WT, et al. An oncological view on the blood-testis barrier. *Lancet Oncol* 2002;3:357–363.
- Bussen S, Sutterlin M, Steck T, et al. Semen parameters in patients with unilateral testicular cancer compared to patients with other malignancies. *Arch Gynecol Obstet* 2004;269:196–198.
- Meistrich ML. Potential genetic risks of using semen collected during chemotherapy. *Hum Reprod* 1993;8:8–10.
- Meistrich ML, Wilson G, Brown BW, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. *Cancer* 1992;70:2703–2712.
- Wang J, Galil KA, Setchell BP. Changes in testicular blood flow and testosterone production during spermatogenesis after irradiation. *J Endocrinol* 1983;98:35–46.
- Bujan L, Walschaerts M, Moinard N, et al. Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. *Fertil Steril* 2013;100:673–680.
- Di Bisceglie C, Bertagna A, Composto ER, et al. Effects of oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders. *Asian J Androl* 2013;15:425–429.
- Marmor D, Grob-Mendez F, Duyck F, et al. Very late return of spermatogenesis after chlorambucil therapy: case reports. *Fertil Steril* 1992;58:845–846.
- Brannigan RE. Fertility preservation in adult male cancer patients. *Cancer Treat Res* 2007;138:28–49.
- Marmor D, Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. *Andrologia* 1995;27:99–106.
- Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. *Bone Marrow Transplant* 2002;30:447–451.
- Pryzant RM, Meistrich ML, Wilson G, et al. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. *J Clin Oncol* 1993;11:239–247.
- Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. *J Clin Oncol* 1997;15:239–245.
- Jacobsen KD, Theodorsen L, Fossa SD. Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. *J Urol* 2001;165:93–96.
- Jacobsen KD, Ous S, Waehre H, et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. *Br J Cancer* 1999;80:249–255.
- Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. *J Clin Oncol* 1997;15:3488–3495.
- Howell SJ, Shalet SM. Effect of cancer therapy on pituitary-testicular axis. *Int J Androl* 2002;25:269–276.
- Hansen PV, Trykker H, Svenekjaer IL, et al. Long-term recovery of spermatogenesis after radiotherapy in patients with testicular cancer. *Radiother Oncol* 1990;18:117–125.
- Marina S, Barcelo P. Permanent sterility after immunosuppressive therapy. *Int J Androl* 1979;2:6.
- Buchanan JD, Fairley KF, Barrie JU. Return of spermatogenesis after stopping cyclophosphamide therapy. *Lancet* 1975;2:156–157.
- da Cunha MF, Meistrich ML, Fuller LM, et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. *J Clin Oncol* 1984;2:571–577.
- Hansen PV, Trykker H, Helkjoer PE, et al. Testicular function in patients with testicular cancer treated with orchiectomy alone or orchiectomy plus cisplatin-based chemotherapy. *J Natl Cancer Inst* 1989;81:1246–1250.
- Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. *Blood* 1996;87:3045–3052.
- Longhi A, Macchiagodena M, Vitali G, et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. *J Pediatr Hematol Oncol* 2003;25:292–296.
- Ahmed SR, Shalet SM, Campbell RH, et al. Primary gonadal damage following treatment of brain tumors in childhood. *J Pediatr* 1983;103:562–565.
- Meistrich ML, van Beek MEAB. Radiation sensitivity of the human testis. *Adv Radiat Biol* 1990;14:227–268.
- Gordon W Jr, Siegmund K, Stanisic TH, et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. *Int J Radiat Oncol Biol Phys* 1997;38:83–94.
- Petersen PM, Giwereman A, Daugaard G, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. *J Clin Oncol* 2002;20:1537–1543.
- Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages. *Acta Anat (Basel)* 1952;14:108–123.
- Tilly JL, Kolesnick RN. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. *Biochim Biophys Acta* 2002;1585:135–138.
- Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary? *Hum Reprod Update* 2012;18:525–535.
- Children's Oncology Group. *Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers*. Version 3.0. www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf.
- Brougham MF, Crofton PM, Johnson EJ, et al. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. *J Clin Endocrinol Metab* 2012;97:2059–2067.
- Sanders JE. Growth and development after hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. *Hematopoietic Cell Transplantation*. Malden, MA: Blackwell Science; 1999.
- Schilsky RL, Sherins RJ, Hubbard SM, et al. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. *Am J Med* 1981;71:552–556.
- Kuhajda FP, Haupt HM, Moore GW, et al. Gonadal morphology in patients receiving chemotherapy for leukemia. Evidence for reproductive potential and against a testicular tumor sanctuary. *Am J Med* 1982;72:759–767.
- Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. *J Natl Cancer Inst* 2006;98:890–896.
- Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. *Am J Obstet Gynecol* 1992;166:788–793.
- Howell SJ, Berger G, Adams JE, et al. Bone mineral density in women with cytotoxic-induced ovarian failure. *Clin Endocrinol (Oxf)* 1998;49:397–402.
- Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. *Cancer* 1977;39:1403–1409.
- Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. *J Clin Oncol* 1988;6:813–818.
- Wallace WH, Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cis-platinum. *Med Pediatr Oncol* 1989;17:409–413.
- Shamberger RC, Rosenberg SA, Seipp CA, et al. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. *Cancer Treat Rep* 1981;65:739–746.
- Choo YC, Chan SY, Wong LC, et al. Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213). *Cancer* 1985;55:2348–2352.
- Bonadonna G, Santoro A, Viviani S, et al. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. *Arch Toxicol Suppl* 1984;7:140–145.
- Specht L, Hansen MM, Geisler C. Ovarian function in young women in long-term remission after treatment for Hodgkin's disease stage I or II. *Scand J Haematol* 1984;32:265–270.
- Morice P, Juncker L, Rey A, et al. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. *Fertil Steril* 2000;74:743–748.
- Spinelli S, Chiodi S, Bacigalupo A, et al. Ovarian recovery after total body irradiation and allogeneic bone marrow transplantation: long-term follow up of 79 females. *Bone Marrow Transplant* 1994;14:373–380.
- Longo DL, Glatstein E, Duffey PL, et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. *J Clin Oncol* 1997;15:3338–3346.
- Horning SJ, Hoppe RT, Kaplan HS, et al. Female reproductive potential after treatment for Hodgkin's disease. *N Engl J Med* 1981;304:1377–1382.

60. Kreuser ED, Xiros N, Hetzel WD, et al. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. *J Cancer Res Clin Oncol* 1987;113:260–266.
61. Jaffe N, Sullivan MP, Ried H, et al. Male reproductive function in long-term survivors of childhood cancer. *Med Pediatr Oncol* 1988;16:241–247.
62. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. *Int J Radiat Oncol Biol Phys* 1990;19:873–880.
63. Siimes MA, Dunkel L, Rautonen J. Risk factors for endocrine testicular dysfunction in adolescent and adult males who have survived malignancies in childhood. *Cancer J* 1992;5:28–31.
64. Muller J, Skakkebaek NE, Hertz H. Initiation of spermatogenesis during chemotherapy for leukemia. *Acta Paediatr Scand* 1985;74:956–960.
65. Gerres L, Bramswig JH, Schlegel W, et al. The effects of epidoscope on testicular function in boys treated for Hodgkin's disease. *Cancer* 1998;83:2217–2222.
66. Thomas-Teinturier C, El Fayeh C, Oberlin O, et al. Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature. *Hum Reprod* 2013;28:488–495.
67. Green DM, Sklar CA, Boice JD Jr, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. *J Clin Oncol* 2009;27:2374–2381.
68. Stillman RJ, Schinfeld JS, Schiff I, et al. Ovarian failure in long-term survivors of childhood malignancy. *Am J Obstet Gynecol* 1981;139:62–66.
69. Couto-Silva AC, Trivin C, Thibaud E, et al. Factors affecting gonadal function after bone marrow transplantation during childhood. *Bone Marrow Transplant* 2001;28:67–75.
70. Watson AR, Taylor J, Rance CP, et al. Gonadal function in women treated with cyclophosphamide for childhood nephrotic syndrome: a long-term follow-up study. *Fertil Steril* 1986;46:331–333.
71. Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group. *J Clin Oncol* 1990;8:1971–1980.
72. Clayton PE, Shalet SM, Price DA, et al. Ovarian function following chemotherapy for childhood brain tumours. *Med Pediatr Oncol* 1989;17:92–96.
73. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. *Med Pediatr Oncol* 1996;27:74–78.
74. Urbano MT, Tait DM. Can the irradiated uterus sustain a pregnancy? A literature review. *Clin Oncol (R Coll Radiol)* 2004;16:24–28.
75. Critchley HO. Factors of importance for implantation and problems after treatment for childhood cancer. *Med Pediatr Oncol* 1999;33:9–14.
76. Mauras N, Sabio H, Rogol AD. Neuroendocrine function in survivors of childhood acute lymphocytic leukemia and non-Hodgkin's lymphoma: a study of pulsatile growth hormone and gonadotropin secretions. *Am J Pediatr Hematol Oncol* 1988;10:9–17.
77. Schmiegelow M, Lassen S, Poulsen HS, et al. Gonadal status in male survivors following childhood brain tumors. *J Clin Endocrinol Metab* 2001;86:2446–2452.
78. Lantering B, Jansson C, Rosberg S, et al. Increased LH and FSH secretion after cranial irradiation in boys. *Med Pediatr Oncol* 1997;29:280–287.
79. Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. *N Engl J Med* 1993;328:87–94.
80. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. *Eur J Cancer Clin Oncol* 1985;21:601–605.
81. Radford JA, Clark S, Crowther D, et al. Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. *Br J Cancer* 1994;69:379–381.
82. Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? *Radiother Oncol* 1999;50:349–353.
83. Bisharah M, Tulandi T. Laparoscopic preservation of ovarian function: an underused procedure. *Am J Obstet Gynecol* 2003;188:367–370.
84. Morice P, Thiam-Ba R, Castaigne D, et al. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. *Hum Reprod* 1998;13:660–663.
85. Terenzianni M, Piva L, Meazza C, et al. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. *Fertil Steril* 2009;91:935.e915–e936.
86. Classe JM, Mahe M, Moreau P, et al. Ovarian transposition by laparoscopy before radiotherapy in the treatment of Hodgkin's disease. *Cancer* 1998;83:1420–1424.
87. Visvanathan DK, Cutner AS, Cassoni AM, et al. A new technique of laparoscopic ovariopexy before irradiation. *Fertil Steril* 2003;79:1204–1206.
88. Molpus KL, Wedergren JS, Carlson MA. Robotically assisted endoscopic ovarian transposition. *JSL S* 2003;7:59–62.
89. Schover LR, Brey K, Lichtin A, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. *J Clin Oncol* 2002;20:1880–1889.
90. Schover LR, Brey K, Lichtin A, et al. Oncologists' attitudes and practices regarding banking sperm before cancer treatment. *J Clin Oncol* 2002;20:1890–1897.
91. Kliesch S, Behre HM, Jurgens H, et al. Cryopreservation of semen from adolescent patients with malignancies. *Med Pediatr Oncol* 1996;26:20–27.
92. Schmiegelow ML, Sommer P, Carlsen E, et al. Penile vibratory stimulation and electroejaculation before anticancer therapy in two pubertal boys. *J Pediatr Hematol Oncol* 1998;20:429–430.
93. Schrader M, Muller M, Straub B, et al. Testicular sperm extraction in azoospermic patients with gonadal germ cell tumors prior to chemotherapy—a new therapy option. *Asian J Androl* 2002;4:9–15.
94. Park YS, Lee SH, Song SJ, et al. Influence of motility on the outcome of in vitro fertilization/intracytoplasmic sperm injection with fresh vs. frozen testicular sperm from men with obstructive azoospermia. *Fertil Steril* 2003;80:526–530.
95. Goossens E, Van Saen D, Tournaye H. Spermatogonial stem cell preservation and transplantation: from research to clinic. *Hum Reprod* 2013;28:897–907.
96. Zapzalka DM, Redmon JB, Pryor JL. A survey of oncologists regarding sperm cryopreservation and assisted reproductive techniques for male cancer patients. *Cancer* 1999;86:1812–1817.
97. Köhler TS, Kondapalli LA, Shah A, et al. Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancer. *J Assist Reprod Genet* 2011;28:269–277.
98. Kim SS. Fertility preservation in female cancer patients: current developments and future directions. *Fertil Steril* 2006;85:1–11.
99. Longhi A, Pignotti E, Versari M, et al. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. *Oncol Rep* 2003;10:151–155.
100. Whitehead E, Shalet SM, Blackledge G, et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. *Cancer* 1983;52:988–993.
101. Ataya K, Rao LV, Lawrence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. *Biol Reprod* 1995;52:365–372.
102. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. *Hum Reprod* 1996;11:1620–1626.
103. Meirov D, Assad G, Dor J, et al. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. *Hum Reprod* 2004;19:1294–1299.
104. Dada T, Salha O, Allgar V, et al. Utero-ovarian blood flow characteristics of pituitary desensitization. *Hum Reprod* 2001;16:1663–1670.
105. Gosden RG, Wade JC, Fraser HM, et al. Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. *Hum Reprod* 1997;12:2483–2488.
106. Oktay K, Sonmez M, Oktem O. 'Ovarian cryopreservation versus ovarian suppression by GnRH analogues: primum non nocere': reply. *Hum Reprod* 2004;19:1681–1683.
107. Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. *Lupus* 2000;9:401–405.
108. Blumenfeld Z, Dann E, Avivi I, et al. Fertility after treatment for Hodgkin's disease. *Ann Oncol* 2002;13:138–147.
109. Pereyra Pacheco B, Mendez Ribas JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. *Gynecol Oncol* 2001;81:391–397.
110. Sauer HJ DR, Gates PL. The preservation of fertility in chemotherapy patients: the use of a gonadotropin releasing hormone antagonist (GnRH-antagonist) cetrorelix for ovarian down-regulation prior to chemotherapy. *J Soc Gynecol Investig* 2006;13:170A–171A.
111. Revel A, Schenker J. Ovarian tissue banking for cancer patients: is ovarian cortex cryopreservation presently justified? *Hum Reprod* 2004;19:14–19.
112. Toft E, Becedas L, Soderstrom M, et al. Glutathione transferase isoenzyme patterns in the rat ovary. *Chem Biol Interact* 1997;108:79–93.
113. Sanger WG, Olson JH, Sherman JK. Semen cryobanking for men with cancer—criteria change. *Fertil Steril* 1992;58:1024–1027.
114. Palermo G, Joris H, Devroey P, et al. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. *Lancet* 1992;340:17–18.
115. Azim AA, Costantini-Ferrando M, Lostritto K, et al. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. *J Clin Endocrinol Metab* 2007;92:2197–2200.
116. Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. *Fertil Steril* 2007;88:657–664.
117. Sonmez M, Atabekoglu C. Assisted reproduction and breast cancer. *Minerva Ginecol* 2007;59:403–414.
118. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. *J Clin Oncol* 2008;26:2630–2635.
119. Stern JE, Brown MB, Wantman E, et al. Live birth rates and birth outcomes by diagnosis using linked cycles from the SART CORS database. *J Assist Reprod Genet* 2013;30:1445–1450.

120. Meseguer M, Molina N, Garcia-Velasco JA, et al. Sperm cryopreservation in oncological patients: a 14-year follow-up study. *Fertil Steril* 2006;85:640–645.
121. Practice Committee Society for Assisted Reproductive Technology, Practice Committee American Society for Reproductive Medicine. Round spermatid nucleus injection (ROSNI). *Fertil Steril* 2003;80:687–689.
122. Lobo RA. Potential options for preservation of fertility in women. *N Engl J Med* 2005;353:64–73.
123. Practice Committees of American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. *Fertil Steril* 2013;99:37–43.
124. Solé M, Santaló J, Boada M, et al. How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achieved with fresh versus vitrified sibling oocytes. *Hum Reprod* 2013;28:2087–2092.
125. Hansen M, Kurinczuk JJ, Milne E, et al. Assisted reproductive technology and birth defects: a systematic review and meta-analysis. *Hum Reprod Update* 2013;19:330–353.
126. Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. *N Engl J Med* 2012;366:1803–1813.
127. Retzlaff MG, Hornstein MD. Is intracytoplasmic sperm injection safe? *Fertil Steril* 2003;80:851–859.
128. Baird DT, Webb R, Campbell BK, et al. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at -196 C. *Endocrinology* 1999;140:462–471.
129. Donnez J, Silber S, Andersen CY, et al. Children born after autotransplantation of cryopreserved ovarian tissue. A review of 13 live births. *Ann Med* 2011;43:437–450.
130. Silber SJ. Ovary cryopreservation and transplantation for fertility preservation. *Mol Hum Reprod* 2012;18:59–67.
131. Bastings L, Beerendonk CC, Westphal JR, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. *Hum Reprod Update* 2013;19:483–506.
132. Oktay K. Ovarian tissue cryopreservation and transplantation: preliminary findings and implications for cancer patients. *Hum Reprod Update* 2001;7:526–534.
133. Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. *N Engl J Med* 2000;342:1919.
134. Radford JA, Lieberman BA, Brison DR, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. *Lancet* 2001;357:1172–1175.
135. Gosden RG, Baird DT, Wade JC, et al. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at -196 degrees C. *Hum Reprod* 1994;9:597–603.
136. Gunasena KT, Villines PM, Critser ES, et al. Live births after autologous transplant of cryopreserved mouse ovaries. *Hum Reprod* 1997;12:101–106.
137. Shaw JM, Cox SL, Trounson AO, et al. Evaluation of the long-term function of cryopreserved ovarian grafts in the mouse, implications for human applications. *Mol Cell Endocrinol* 2000;161:103–110.
138. Lee DM, Yeoman RR, Battaglia DE, et al. Live birth after ovarian tissue transplant. *Nature* 2004;428:137–138.
139. Silber SJ, Gosden RG. Ovarian transplantation in a series of monozygotic twins discordant for ovarian failure. *N Engl J Med* 2007;356:1382–1384.
140. Demeestere I, Simon P, Emiliani S, et al. Orthotopic and heterotopic ovarian tissue transplantation. *Hum Reprod Update* 2009;15:649–665.
141. Rosendahl M, Loft A, Byskov AG, et al. Biochemical pregnancy after fertilization of an oocyte aspirated from a heterotopic autotransplant of cryopreserved ovarian tissue: case report. *Hum Reprod* 2006;21:2006–2009.
142. Andersen CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. *Hum Reprod* 2008;23:2266–2272.
143. Stern CJ, Gook D, Hale LG, et al. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. *Hum Reprod* 2013;28:2996–2999.
144. Candy CJ, Wood MJ, Whittingham DG. Effect of cryoprotectants on the survival of follicles in frozen mouse ovaries. *J Reprod Fertil* 1997;110:11–19.
145. Wang X, Bilolo KK, Qi S, et al. Restoration of fertility in oophorectomized rats after tubo-ovarian transplantation. *Microsurgery* 2002;22:30–33.
146. Bedaiwy MA, Jeremias E, Gurnuluoglu R, et al. Restoration of ovarian function after autotransplantation of intact frozen-thawed sheep ovaries with microvascular anastomosis. *Fertil Steril* 2003;79:594–602.
147. Arav A, Gavish Z, Elami A, et al. Ovarian function 6 years after cryopreservation and transplantation of whole sheep ovaries. *Reprod Biomed Online* 2010;20:48–52.
148. Cha KY, Koo JJ, Ko JJ, et al. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. *Fertil Steril* 1991;55:109–113.
149. Yang SH, Qin SL, Xu Y, et al. Healthy live birth from vitrified blastocysts produced from natural cycle IVF/IVM. *Reprod Biomed Online* 2010;20:656–659.
150. Chian RC, Huang JY, Gilbert L, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. *Fertil Steril* 2009;91:2391–2398.
151. Cao Y, Xing Q, Zhang ZG, et al. Cryopreservation of immature and in-vitro matured human oocytes by vitrification. *Reprod Biomed Online* 2009;19:369–373.
152. Hubner K, Fuhrmann G, Christenson LK, et al. Derivation of oocytes from mouse embryonic stem cells. *Science* 2003;300:1251–1256.
153. White YA, Woods DC, Takai Y, et al. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. *Nat Med* 2012;18:413–421.
154. Avarbuck MR, Brinster CJ, Brinster RL. Reconstitution of spermatogenesis from frozen spermatogonial stem cells. *Nat Med* 1996;2:693–696.
155. Schlatt S, Foppiani L, Rolf C, et al. Germ cell transplantation into X-irradiated monkey testes. *Hum Reprod* 2002;17:55–62.
156. Jahnukainen K, Hou M, Petersen C, et al. Intratesticular transplantation of testicular cells from leukemic rats causes transmission of leukemia. *Cancer Res* 2001;61:706–710.
157. Nagano M, Patrizio P, Brinster RL. Long-term survival of human spermatogonial stem cells in mouse testes. *Fertil Steril* 2002;78:1225–1233.
158. Honaramooz A, Snedaker A, Boiani M, et al. Sperm from neonatal mammalian testes grafted in mice. *Nature* 2002;418:778–781.
159. Cremades N, Sousa M, Bernabeu R, et al. Developmental potential of elongating and elongated spermatids obtained after in-vitro maturation of isolated round spermatids. *Hum Reprod* 2001;16:1938–1944.
160. Feng LX, Chen Y, Dettin L, et al. Generation and in vitro differentiation of a spermatogonial cell line. *Science* 2002;297:392–395.
161. Toyooka Y, Tsunekawa N, Akasu R, et al. Embryonic stem cells can form germ cells in vitro. *Proc Natl Acad Sci U S A* 2003;100:11457–11462.
162. Meistrich ML, Shetty G. Suppression of testosterone stimulates recovery of spermatogenesis after cancer treatment. *Int J Androl* 2003;26:141–146.
163. Meistrich ML, Wilson C, Kangasniemi M, et al. Mechanism of protection of rat spermatogenesis by hormonal pretreatment: stimulation of spermatogonial differentiation after irradiation. *J Androl* 2000;21:464–469.
164. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. *Ann Intern Med* 1997;126:292–295.
165. Howell SJ, Shalet SM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. *Curr Oncol Rep* 2002;4:443–452.
166. Thomson AB, Anderson RA, Irvine DS, et al. Investigation of suppression of the hypothalamic-pituitary-gonadal axis to restore spermatogenesis in azoospermic men treated for childhood cancer. *Hum Reprod* 2002;17:1715–1723.
167. Kamischke A, Kuhlmann M, Weinbauer GF, et al. Gonadal protection from radiation by GnRH antagonist or recombinant human FSH: a controlled trial in a male nonhuman primate (*Macaca fascicularis*). *J Endocrinol* 2003;179:183–194.
168. Badawy A, Elmashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. *Fertil Steril* 2009;91:694–697.
169. Sverrisdottir A, Nystedt M, Johansson H, et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. *Breast Cancer Res Treat* 2009;117:561–567.
170. Peccatori F, Demeestere I. GnRH analogue for chemotherapy-induced ovarian damage: too early to say? *Fertil Steril* 2009;92:e33.
171. Oktay K, Sonmezer M. Questioning GnRH analogs for gonadal protection in cancer patients. *Fertil Steril* 2009;92:e32.
172. Moore HC. Do GnRH analogs protect against ovarian toxicity of chemotherapy? *Breast Cancer Res Treat* 2009;117:569–570.
173. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. *Fertil Steril* 2011;95:906–914.e1–e4.
174. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBC 37 ZORO study. *J Clin Oncol* 2011;29:2334–2341.
175. Balkenende E, Dahhan T, van der Veen F, et al. Comment on GnRH analogue cotreatment with chemotherapy for preservation of ovarian function. *Fertil Steril* 2011;96:e155–e156.
176. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadotropin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. *Obstet Gynecol* 2013;121:78–86.
177. Shepherd JH, Milliken DA. Conservative surgery for carcinoma of the cervix. *Clin Oncol (R Coll Radiol)* 2008;20:395–400.
178. Gien LT, Covens A. Fertility-sparing options for early stage cervical cancer. *Gynecol Oncol* 2010;117:350–357.
179. Magrina JF, Goodrich MA, Lidner TK, et al. Modified radical hysterectomy in the treatment of early squamous cervical cancer. *Gynecol Oncol* 1999;72:183–186.
180. Dargent D, Brun JL, Roy M, et al. The trachelectomy enlarged, an alternative to radical hysterectomy in the treatment of invasive cancers developed on the outer surface of the cervix. *J Obstet Gynecol* 1994;2:285–292.
181. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321–333.
182. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women's Health Initiative randomized trials. *JAMA* 2013;310:1353–1368.
183. Mulder JE. Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. *Med Pediatr Oncol* 1999;33:46–52.

184. Fahlén M, Formander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. *Eur J Cancer* 2013;49:52–59.
185. Howell SJ, Radford JA, Adams JE, et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. *Clin Endocrinol (Oxf)* 2001;55:315–324.
186. Lange PH, Narayan P, Fraley EE. Fertility issues following therapy for testicular cancer. *Semin Urol* 1984;2:264–274.
187. Miron V, Imbimbo C, Palmieri A, et al. Erectile dysfunction after surgical treatment. *Int J Androl* 2003;26:137–140.
188. Walsh PC, Mostwin JL. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. *Br J Urol* 1984;56:694–697.
189. Chang DW, Wood CC, Kroll SS, et al. Cavernous nerve reconstruction to preserve erectile function following non-nerve sparing radical retropubic prostatectomy: a prospective study. *Plast Reconstr Surg* 2003;111:1174–1181.
190. Brock C, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. *J Urol* 2003;170:1278–1283.
191. Magelssen H, Brydoy M, Fossa SD. The effects of cancer and cancer treatments on male reproductive function. *Nat Clin Pract Urol* 2006;3:312–322.
192. Ochsenuhn R, Kamischke A, Nieschlag E. Imipramine for successful treatment of retrograde ejaculation caused by retroperitoneal surgery. *Int J Androl* 1999;22:173–177.
193. Jefferys A, Siassakos D, Wardle P. The management of retrograde ejaculation: a systematic review and update. *Fertil Steril* 2012;97:306–312.
194. Gilja I, Parazajder J, Radej M, et al. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. *Eur Urol* 1994;25:226–228.
195. Ohl DA, Wolf LJ, Menge AC, et al. Electroejaculation and assisted reproductive technologies in the treatment of anejaculatory infertility. *Fertil Steril* 2001;76:1249–1255.
196. Witt KL, Bishop JB. Mutagenicity of anticancer drugs in mammalian germ cells. *Mutat Res* 1996;355:209–234.
197. Committee on the Biological Effects of Ionizing Radiations. *Health Effects of Exposure to Low Levels of Ionizing Radiation: BEIR V*. Washington, DC: National Academy Press; 1990.
198. Tempest HG, Ko E, Chan P, et al. Sperm aneuploidy frequencies analysed before and after chemotherapy in testicular cancer and Hodgkin's lymphoma patients. *Hum Reprod* 2008;23:251–258.
199. Stahl O, Eberhard J, Jepson K, et al. Sperm DNA integrity in testicular cancer patients. *Hum Reprod* 2006;21:3199–3205.
200. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. *Med Pediatr Oncol* 1999;33:29–33.
201. Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. *Am J Hum Genet* 1998;62:45–52.
202. Meistrich ML, Byrne J. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies. *Am J Hum Genet* 2002;70:1069–1071.
203. Rustin GJ, Booth M, Dent J, et al. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. *Br Med J (Clin Res Ed)* 1984;288:103–106.
204. Senturia YD, Peckham CS, Peckham MJ. Children fathered by men treated for testicular cancer. *Lancet* 1985;2:766–769.
205. Dodds L, Marrett LD, Tomkins DJ, et al. Case-control study of congenital anomalies in children of cancer patients. *BMJ* 1993;307:164–168.
206. Schull WJ. The children of atomic bomb survivors: a synopsis. *J Radiol Prot* 2003;23:369–384.
207. Yamazaki JN, Schull WJ. Perinatal loss and neurological abnormalities among children of the atomic bomb. Nagasaki and Hiroshima revisited, 1949 to 1989. *JAMA* 1990;264:605–609.
208. Keleher AJ, Theriault RL, Gwyn KM, et al. Multidisciplinary management of breast cancer concurrent with pregnancy. *J Am Coll Surg* 2002;194:54–64.
209. Brandriff BF, Meistrich ML, Gordon LA, et al. Chromosomal damage in sperm of patients surviving Hodgkin's disease following MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) therapy with and without radiotherapy. *Hum Genet* 1994;93:295–299.
210. Frias S, Van Hummelen P, Meistrich ML, et al. NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. *Cancer Res* 2003;63:44–51.
211. Robbins WA, Meistrich ML, Moore D, et al. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. *Nat Genet* 1997;16:74–78.